Background: The concept of mixed adenoneuroendocrine carcinoma (MANEC) was introduced in the 2010 World Health Organization classification of digestive neuroendocrine neoplasms. Bile duct invasion by MANEC is exceptionally rare. We herein report a case of MANEC with invasion of multiple bile ducts. Case presentation: A 60-year-old man presented with a 7-day history of upper abdominal pain, and a mass in the cystic duct was suspected based on computed tomography findings. The patient underwent resection of the extrahepatic bile ducts with concomitant radical lymphadenectomy and Roux-en-Y cholangiojejunostomy. Large cell neuroendocrine carcinoma was detected in a component of the resected tumor. According to the pathological and immunohistochemical features of the tumor, the final histopathological diagnosis was a biliary MANEC, tumor stage T2N0M1 (Stage IIIC). The patient recovered uneventfully and was discharged from the hospital 10 days after surgery. Conclusions: We have described a rare case of extrahepatic MANEC invading multiple bile ducts, with particular emphasis on the physician's awareness of MANEC and its optimal treatment. MANEC arising from extrahepatic bile ducts is rare, and surgical resection is the most effective treatment method.
Background
Mixed adenoneuroendocrine carcinomas (MANECs) are defined as composite neoplasms with areas of adenocarcinoma or squamous cell carcinoma intermingled with neuroendocrine carcinoma (NEC) or neuroendocrine tumor (NET), each comprising at least 30% of the neoplasm. 1 Since the concept of MANEC was introduced in 2010, 1 cases of MANEC have been continuously reported. MANECs usually develop in the colon or stomach [2] [3] [4] ; those in the bile ducts are exceptionally rare. In one report, MANEC originating from the extrahepatic bile duct was poorly differentiated, malignant, and invasive. 5 To our knowledge, no reports have described simultaneous invasion of MANEC into the cystic duct, common bile duct (CBD), and common hepatic duct (CHD). We herein describe a biliary MANEC with invasion of multiple bile ducts and review the current literature of MANECs.
Case presentation
A 60-year-old man presented with a 1-week history of abdominal distension. The patient had no family history of cancer. His relevant medical history included a 2-year duration of type 2 diabetes mellitus and a myocardial 
Pathologic findings
Macroscopic examination showed a cauliflower-like, solid mass measuring 1.7 Â 1.5 Â 0.3 cm in the distal CHD, proximal CBD, and cystic duct. No gallstones were identified in either the gallbladder or bile ducts. Histological examination revealed two cell populations. Moderately to poorly differentiated adenocarcinoma comprised the main component (approximately 65% of the whole tumor). The other component was large cell NEC (>30% of the whole tumor). The neuroendocrine component was arranged a nest pattern distributed into the adenocarcinoma component, without regularity in the arrangement (Figure 2(a) ). The NET cells showed cytomorphologic features of oval cells, abundant eosinophilic cytoplasm, and partial vacuolation of the nucleus (Figure 2(b) ). The mitotic rate of cancer cells was 10 to 20 cells per 10 highpower fields (Figure 2(c) ). Cancer cells were detected in the lymph nodes (No. 12) adjacent to the cystic duct, while the other regional lymph nodes (Nos. 8, 9, and 13) were free of cancer cells. Immunohistochemically, the Ki-67 labeling index was 70% in the whole tumor, indicating strong proliferative activity (Figure 2(d) ). The large cell NEC component was positive for chromogranin A (CgA) and synaptophysin (Syn), while the adenocarcinoma components were negative for CgA and Syn (Figure 2 
Discussion and conclusions
Biliary MANEC is extremely rare, and only a few cases have been reported to date. 6 According to the latest World Health Organization classification, MANEC is graded as an NET. 1 The most common histologic subtype of NET of the extrahepatic bile ducts is small cell NET; only a few cases of large cell NET of the CBD have been reported. 7 The most frequent sites of extrahepatic biliary NETs are the CBD and the distal CBD (19.2%), followed by the middle CBD (17.9%), the cystic duct (16.7%), and the proximal CBD (11.5%). 8 Previously reported cases of MANEC have described localization of the tumor at either the extrahepatic biliary duct or intrahepatic biliary duct. 9, 10 With respect to the growth pattern of the MANEC components within the tumor, the adenocarcinoma component is generally located in the superficial portion of the neoplasm, while the NEC component is mainly located in the deeper portion of the tumor. 7, 11 In the present case of an extrahepatic MANEC, the tumor was growing in the cystic duct, CBD, and CHD simultaneously. The NEC components showed a nest pattern and were distributed separately in the deeper portion of the tumor. The large cell NEC component accounted for >30% of the whole tumor. To the best of our knowledge, no such case has been previously reported.
Because of the absence of specific serum markers, preoperative diagnosis of MANEC is difficult. 12 A preoperative diagnosis may be made by examining brush cytology specimens, but this method has a high false-negative rate and is not a conventional method. 13 Contrast CT is a useful tool for diagnosis of cholangiocarcinoma, which is enhanced only in the delayed phase.
14 Immunohistochemistry is the main diagnostic method for MANECs. 12 Because both the small and large cell pure neuroendocrine components are diffusely positive for Syn and usually for CgA, at least two of three commonly used neuroendocrine markers (Syn, CgA, or CD56) must be abundantly expressed to establish a diagnosis of high-grade MANEC.
1 Measurement of neuron-specific enolase is generally excluded because of its poor specificity. In the present case, both Syn and CgA showed strong immunohistochemical positivity in the nest growth pattern of the NEC components but negativity in the adenocarcinoma components, confirming the diagnosis of MANEC.
The prognosis of MANECs has not been thoroughly studied because of the rarity of this tumor. 10 However, the prognosis of NEC of the bile duct appears to be poor. In one case report and literature review, 7 57% (12/21) of affected patients died from 3 to 20 months postoperatively, and only two patients reportedly survived for >2 years. In addition, NEC in the biliary system has a high incidence of distant metastasis. 7 The prognosis might be related to the proliferative fraction of the tumor. In one case, a patient with MANEC survived for 45 months after surgery because the tumor showed a low proliferative fraction (Ki-67 labeling index of 9.6%). 15 In fact, the proliferation rate has been shown to provide significant prognostic information in patients with NEC. 16 In terms of therapy for MANECs, surgical resection is the most effective treatment method. Multidisciplinary treatment consisting of preoperative chemotherapy, adjuvant or neoadjuvant chemotherapy, and radiation therapy may prolong the survival of patients with MANEC. 7, 17 In conclusion, we have herein reported a rare case of a biliary MANEC extensively infiltrating the extrahepatic bile ducts, with particular emphasis on the physician's awareness of MANEC and its optimal treatment. MANEC arising from the extrahepatic bile duct is rare, and surgical resection is the most effective treatment method. Additional studies are required to more conclusively define the optimal management in terms of preoperative diagnosis and therapy for patients with MANECs to achieve improved outcomes.
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